• +1-646-491-9876
    • +91-20-67278686

    Search

    Muscular Dystrophy Pipeline Review H1 2017

    Muscular Dystrophy Pipeline Review H1 2017

    • Report Code ID: RW0001799271
    • Category Pharmaceuticals
    • No. of Pages 138
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Muscular Dystrophy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

    Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 27 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.

    Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 4
    Muscular Dystrophy - Overview 5
    Muscular Dystrophy - Therapeutics Development 6
    Muscular Dystrophy - Therapeutics Assessment 15
    Muscular Dystrophy - Companies Involved in Therapeutics Development 25
    Muscular Dystrophy - Drug Profiles 38
    Muscular Dystrophy - Dormant Projects 116
    Muscular Dystrophy - Discontinued Products 118
    Muscular Dystrophy - Product Development Milestones 119
    Appendix 131

    List of Tables

    Number of Products under Development for Muscular Dystrophy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H1 2017
    Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H1 2017
    Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H1 2017
    Muscular Dystrophy - Pipeline by aTyr Pharma Inc, H1 2017
    Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H1 2017
    Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd, H1 2017
    Muscular Dystrophy - Pipeline by Biophytis SAS, H1 2017
    Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H1 2017
    Muscular Dystrophy - Pipeline by Evotec AG, H1 2017
    Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H1 2017
    Muscular Dystrophy - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
    Muscular Dystrophy - Pipeline by Genethon SA, H1 2017
    Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Muscular Dystrophy - Pipeline by Marina Biotech Inc, H1 2017
    Muscular Dystrophy - Pipeline by Medestea Research & Production SpA, H1 2017
    Muscular Dystrophy - Pipeline by Novogen Ltd, H1 2017
    Muscular Dystrophy - Pipeline by Pfizer Inc, H1 2017
    Muscular Dystrophy - Pipeline by Prothelia Inc, H1 2017
    Muscular Dystrophy - Pipeline by SanBio Inc, H1 2017
    Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017
    Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H1 2017
    Muscular Dystrophy - Pipeline by Strykagen Corp, H1 2017
    Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
    Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H1 2017
    Muscular Dystrophy - Dormant Projects, H1 2017
    Muscular Dystrophy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Muscular Dystrophy - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Muscular Dystrophy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Acceleron Pharma Inc
    Achelios Therapeutics Inc
    AMO Pharma Ltd
    aTyr Pharma Inc
    Benitec Biopharma Ltd
    Bio Blast Pharma Ltd
    Biophytis SAS
    Corcept Therapeutics Inc
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Fulcrum Therapeutics Inc
    Genervon Biopharmaceuticals LLC
    Genethon SA
    Ionis Pharmaceuticals Inc
    Marina Biotech Inc
    Medestea Research & Production SpA
    Novogen Ltd
    Pfizer Inc
    Prothelia Inc
    SanBio Inc
    Santhera Pharmaceuticals Holding AG
    Sarepta Therapeutics Inc
    Strykagen Corp
    Takeda Pharmaceutical Company Ltd
    Ultragenyx Pharmaceutical Inc
    WAVE Life Sciences Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//muscular-dystrophy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//muscular-dystrophy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//muscular-dystrophy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments